share_log

藥明巨諾-B:更換核數師

JW THERAP-B: CHANGE OF AUDITOR

HKEX ·  Oct 31, 2024 16:30

Summary by Moomoo AI

藥明巨諾-B(股份代號:2126)於2024年10月31日宣布,原核數師羅兵咸永道因未能就2024年財政年度審核酬金達成共識而辭任,該辭任將於同日生效。董事會隨後委任德勤作為新核數師,任期至下屆股東週年大會結束。董事會及審核委員會經評估後認為,德勤具備適當的行業知識、技術能力及獨立性,且更換核數師符合公司及股東整體利益,不會對年度業績報告造成重大影響。
藥明巨諾-B(股份代號:2126)於2024年10月31日宣布,原核數師羅兵咸永道因未能就2024年財政年度審核酬金達成共識而辭任,該辭任將於同日生效。董事會隨後委任德勤作為新核數師,任期至下屆股東週年大會結束。董事會及審核委員會經評估後認為,德勤具備適當的行業知識、技術能力及獨立性,且更換核數師符合公司及股東整體利益,不會對年度業績報告造成重大影響。
WuXi AppTec-B (stock code: 2126) announced on October 31, 2024, that the original auditor PricewaterhouseCoopers had resigned due to the inability to reach a consensus on the audit fees for the 2024 financial year, and the resignation will take effect on the same day. The board of directors subsequently appointed Deloitte as the new auditor, with a term until the end of the next annual general meeting of shareholders. After evaluation, the board of directors and the audit committee believe that Deloitte has the appropriate industry knowledge, technical capabilities, and independence, and that changing auditors is in the overall interest of the company and shareholders, and will not have a significant impact on the annual performance report.
WuXi AppTec-B (stock code: 2126) announced on October 31, 2024, that the original auditor PricewaterhouseCoopers had resigned due to the inability to reach a consensus on the audit fees for the 2024 financial year, and the resignation will take effect on the same day. The board of directors subsequently appointed Deloitte as the new auditor, with a term until the end of the next annual general meeting of shareholders. After evaluation, the board of directors and the audit committee believe that Deloitte has the appropriate industry knowledge, technical capabilities, and independence, and that changing auditors is in the overall interest of the company and shareholders, and will not have a significant impact on the annual performance report.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more